◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral WATCH-LIST MEDIUM

Noopept

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST MEDIUM

For Dylan-archetype, noopept is a credible nootropic with a genuinely interesting mechanism (endogenous-cPG generation, BDNF upregulation, AMPA potentiation) and a strong Russian clinical signal in cognitive impairment populations. But Dylan is already running a Russian-peptide-heavy V5 stack (Semax, Bromantane, Adamax, Selank PRN) that covers the same neurotrophic + cognitive + anxiolytic territory through better-evidenced routes. Noopept's marginal contribution on top of that stack is unclear. Confidence is MEDIUM not HIGH because (a) virtually all human efficacy data is single-source Russian (Ostrovskaya / Zakusov Institute lineage), (b) Western replication is essentially absent, (c) BDNF claims rest on Ostrovskaya animal data with thin healthy-adult human BDNF measurement, (d) the "1000× piracetam" framing is widely misunderstood. Verdict would upgrade to OPTIONAL-ADD if (i) Adamax or Semax fails to deliver subjective benefit and a different-mechanism Russian compound is wanted, or (ii) Dylan wants a sublingual fast-onset option for high-cognitive-demand acute use. Verdict would upgrade to STRONG-CANDIDATE only with independent Western RCT.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    WATCH-LIST

    Mechanism is interesting, evidence is reasonable for Russian-source standards, side-effect profile is clean. *But Dylan is already running Semax + Bromantane + Adamax (planned) + Selank PRN.* Noopept's BDNF/NGF upregulation overlaps significantly with Semax + Adamax; its anxiolytic angle overlaps with Selank + Bromantane GABA arm; its cognitive-clarity angle overlaps with all of the above + modafinil. Marginal contribution on top of Dylan's V5 stack is unclear and probably small. Promote to OPTIONAL-ADD only if (a) Adamax/Semax fail to deliver, (b) Dylan wants a fast-onset sublingual PRN tool that the peptides can't fill, or (c) a bloodwork/genetics finding (Met/Met BDNF, APOE4) suggests stronger response. Confidence MEDIUM not HIGH because all human data is Russian.

  • Dylan20-30, brain-priority, NOT already running Russian peptides
    OPTIONAL-ADD

    Verdict shifts substantially in this profile — noopept is a credible, low-side-effect, oral-convenient cognitive enhancer with a unique endogenous-metabolite mechanism. For someone without Semax/Adamax in their stack, noopept is among the better single-compound Russian nootropic picks.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Same logic — clean PRN tool for high-cognitive-demand windows. Slightly stronger fit than for Dylan because age-related BDNF/cholinergic decline begins to show. Daily use becomes more justifiable.

  • 50+, mild cognitive decline
    STRONG-CANDIDATE

    This is closer to the original Russian indication. Ostrovskaya cognitive impairment trials support use for vascular and degenerative MCI — modest evidence base but the strongest noopept signal exists in this population. Can be daily with periodic bloodwork.

  • Anxiety-prone
    OPTIONAL-ADD

    with caution. Anxiolytic component is real but mild; Selank (peptide) is the better Russian pick for anxiety + cognition. If pure-cognitive enhancement is also wanted, noopept may be a more efficient single-compound option than separate cognitive-enhancer + anxiolytic.

  • High athletic load, tested status
    OPTIONAL-ADD

    not WADA-banned. Noopept is not on the WADA prohibited list (compare bromantane). Safe for tested athletes. Skill-acquisition / cognitive-recovery rationale plausible.

  • Sleep-disordered
    CAUTION

    Mild alerting effect at the dose level can clip sleep onset if dosed afternoon/evening. Strict AM + early-PM dosing rule. If insomnia-prone, dose only in the morning.

  • Recovery-focused (post-injury, post-illness, post-concussion)
    STRONG-CANDIDATE

    BDNF/NGF + AMPA + neuroprotective profile is well-suited; Russian clinical use in post-stroke and post-TBI cognitive recovery is the strongest noopept rationale for this profile. For Dylan's MMA subconcussive context, this rationale exists but is already covered by Semax + Adamax + Cerebrolysin in the V5 plan.

  • Strength/anabolic-focused
    NEUTRAL

    No anabolic mechanism, no hormonal effect. No athletic-performance angle beyond cognitive/skill-acquisition.

▸ Subjective experience (deep)

Onset: 15–30 minutes sublingual; 60–90 minutes oral. Some users report "first hit" within 10 minutes sublingual.

Peak: 30–90 minutes. Subjective duration 4–8 hours per dose; effects compound across days/weeks of consistent dosing as BDNF transcription accumulates.

Characteristic phenomenology (compiled from anecdote + Russian clinical descriptors):

  • Rapid clarity (not stim-like). Most-reported effect — "fog lifts," easier task initiation, smoother thought-to-output flow. Distinct from caffeine or modafinil signature.
  • Verbal fluency lift. Frequently reported; smoother retrieval of less-frequently-used vocabulary, easier explanation of complex ideas. Less pronounced than pramiracetam's verbal effect but faster onset.
  • Mild mood lift / anxiolytic edge. Calm-confidence rather than stim-rush. Some users describe "lower internal noise" — less rumination, less reactive emotional response.
  • Memory access improvement. Both working memory (holding more in mind) and longer-term recall (names, prior conversations). Magnitude is modest in healthy adults; more pronounced in cognitive-impairment populations.
  • Subtle, not obvious. A frequent biohacker complaint: "doesn't feel like it's doing anything" but productivity/output differences are noticed in hindsight. Different signature from modafinil's "obviously on something." Mechanistically consistent with BDNF-driven baseline shift rather than acute stimulation.
  • Cumulative effect. First-dose response is usually mild; full subjective profile emerges by day 5–10 of consistent dosing.
  • Failure to respond (~20–30%). Real failure mode. If 4 weeks of consistent dosing at 20–30 mg/day produces no subjective shift, noopept is unlikely to be a high-yield compound for that individual.

Compared to other nootropics (Dylan-relevant):

  • vs Semax: Similar BDNF mechanism but different delivery (oral dipeptide vs intranasal heptapeptide). Semax has stronger Russian clinical evidence; noopept has the endogenous-metabolite advantage and oral convenience. Subjective overlap is significant — both produce "calm clarity" rather than stim-energy.
  • vs Bromantane: Different mechanism (synthesis-side DA vs neurotrophic/AMPA). Bromantane is more "motivated focus"; noopept is more "clear thinking + anxiolytic." Stack-compatible; non-redundant in mechanism.
  • vs Piracetam: Mass-basis ~1000× more potent (10–30 mg vs 1.6–4.8 g typical doses); per-effect magnitude is not 1000× — more like 2–5× by user reports. Faster onset, more anxiolytic, stronger subjective effect at equivalent CNS exposure. (See Controversies.)
  • vs Pramiracetam: Different mechanism (HACU-enhancement vs cPG/AMPA/BDNF). Pramiracetam is more "verbal/memory cholinergic"; noopept is more "trophic/calm." Both PRN-friendly; non-redundant.
  • vs Phenylpiracetam: Phenylpiracetam is acute-stim-like with rapid tolerance; noopept is sustained-cognitive without tolerance. Different use cases.
  • vs modafinil: Entirely different. Modafinil is wakefulness/drive; noopept is trophic/clarity. Stack-compatible, no overlap.
▸ Tolerance + cycling deep dive
  • Tolerance buildup: minimal-to-mild in available data. Mechanism (transcriptional upregulation of BDNF, AMPA modulation, endogenous cPG augmentation) is not classical receptor-agonism, so post-synaptic downregulation is not expected. Anecdotal reports describe mild cumulative tolerance over weeks-to-months of daily use — typically expressed as "the edge fades, but the baseline benefit holds." 1–2 week washout reportedly resets subjective sensitivity to baseline.
  • Cross-tolerance: Partial overlap with AMPA-modulating racetams (aniracetam, oxiracetam) and with classical racetams via shared cholinergic mechanisms. Phenylpiracetam shows the fastest tolerance and should not be daily-stacked with noopept.
  • Recommended cycle for Dylan (if added): PRN-only or short pulse, not daily. 4 weeks on / 1–2 weeks off as initial pattern. If escalating to daily continuous, match Russian clinical cycle (1.5–3 months on, 1 month off) and reassess after 8 weeks.
  • Reset protocol if needed: 2-week complete washout. Subjective effect typically returns to baseline freshness. No physical dependence, no withdrawal syndrome documented.
▸ Stacking deep dive

Synergistic with

  • citicoline (Dylan's V4 daily 500 mg): Recommended cofactor. Choline demand is lower than for classical racetams but still relevant. Already in Dylan's V4 stack — direct fit. Reduces headache risk.
  • alpha-gpc: Alternative choline cofactor; faster ACh substrate provision. Either citicoline OR alpha-GPC works; alpha-GPC has a small subjective edge for some.
  • DHA / fish oil (Dylan's V4): Membrane phospholipid substrate for hippocampal neurons; combines well with the BDNF/trophic angle.
  • Phosphatidylserine (Dylan's V4): Membrane phospholipid + cortisol modulation; theoretically synergistic with BDNF-mediated stress resilience.
  • L-theanine (Dylan's V4): Smooths the rare irritability some users get on noopept; complementary GABA-tone support.
  • Cerebrolysin (Dylan's V5 quarterly cycle): Different mechanism (peptide fragments + neurotrophic milieu vs cPG/AMPA/BDNF). Theoretical synergy — Russian clinical practice routinely combines them. Both target the trophic axis through different routes.

Avoid stacking with (or caution)

  • Multiple racetams simultaneously (e.g., daily piracetam + noopept + pramiracetam): Partial mechanism overlap (AMPA + cholinergic); diminishing returns and additive choline depletion. Pick one cognitive enhancer at a time. For Dylan: if running noopept, take a break from any other racetam. (Not currently relevant — Dylan's V5 doesn't include daily racetams.)
  • Phenylpiracetam (daily): Same logic — phenylpiracetam tolerates fast and shares partial mechanism. PRN co-use is fine if separated by days.
  • Adamax / Semax (daily): Mechanism overlap (BDNF/NGF upregulation) is the main concern. Not strictly contraindicated but probably mechanism-redundant — running noopept on top of Adamax+Semax adds cost and complexity without proportional benefit for Dylan-archetype. This is the central reason for Dylan's WATCH-LIST verdict.
  • Strong anticholinergics: Pharmacological antagonism — defeats partial cholinergic mechanism.

Neutral / safe co-administration

Magnesium (any form), creatine, vitamin D3, vitamin C, NAC, curcumin, beta-alanine, rhodiola, glycine/tryptophan, taurine, apigenin, astaxanthin — Dylan's full V4 daily core is compatible. Caffeine + L-theanine fully compatible. Modafinil compatible (no overlap). Bromantane compatible (different mechanism — synthesis-side DA vs trophic/AMPA). Selank compatible (anxiolytic peptide, different mechanism). BPC-157 / TB-500 / GHK-Cu peptides — neutral.

▸ Drug interactions deep dive
  • CYP enzymes: No major CYP interactions documented at therapeutic doses. Limited primary literature — treat as low-interaction-likelihood compound but don't assume zero. The dipeptide structure is metabolized largely by peptidases, not CYP enzymes — similar interaction profile to Semax.
  • Hormonal contraceptives: No documented interaction.
  • Anticoagulants (warfarin, DOACs): No documented interaction.
  • Antidepressants: No documented interaction with SSRIs, SNRIs, MAOIs. Non-monoaminergic primary mechanism makes serotonin syndrome biologically implausible. Empirically tolerated in Russian clinical co-prescription.
  • Anticonvulsants: No documented interaction. Noopept is not pro-convulsant; modest anticonvulsant effects have been reported in animal seizure models.
  • Stimulants (modafinil, amphetamines, methylphenidate): No documented interaction; mechanisms are non-overlapping.
  • Alcohol: Russian clinical literature suggests noopept may modestly attenuate ethanol-induced cognitive impairment — empirically not relevant for Dylan (zero baseline).
  • Anesthesia: Limited data. Conservative practice: discontinue 1–2 weeks prior to surgery.
▸ Pharmacogenomics
  • Prolyl-endopeptidase (PREP) polymorphisms: No published clinical data on noopept response by PREP genotype. Theoretically, reduced-function variants might delay or blunt cPG generation — untested.
  • BDNF Val66Met (rs6265): Met-carriers have lower baseline BDNF activity. Theoretically larger relative response to noopept (more headroom for upregulation), but speculative. Worth checking against Dylan's 23andMe results (~June 2026).
  • APOE genotype: Older Russian dementia studies did not stratify by APOE. APOE4 carriers have known cholinergic deficits and might theoretically respond more — untested.
  • COMT Val158Met: Not directly studied with noopept. Less mechanistic relevance than for DA-active compounds (bromantane, modafinil).
  • CYP variants: Limited PK pathway, low pharmacogenomic concern.
  • For Dylan: Once 23andMe results land (~June 2026), check BDNF Val66Met and APOE status. Met-carrier or APOE4-carrier status would weakly increase the case for noopept, but probably not enough to override the stack-redundancy concern with Semax/Adamax.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market (Russian) RUPharma $15–25 / 60 tabs × 10 mg ($0.30/dose) High — top-rated Russian peptide/nootropic vendor, ~200 Trustpilot reviews 5★, "Alexei" responsive, discrete shipping Stocks branded Russian-pharmaceutical-grade Noopept (manufactured by JSC Lekko / similar Russian pharma). 2–4 weeks delivery. Top pick for Dylan — same vendor as his Semax/Adamax order.
Gray-market (Russian) CosmicNootropic ~$20–30 / 50 tabs × 10 mg High — operating since 2016, decent reputation Same Russian pharmaceutical-grade source. Backup if RUPharma stocks out.
Research-chem (US) Nootropics Depot ~$25 / 10 g powder (until banned) / no longer carried as of 2026 N/A (delisted) Status check 2026: Nootropics Depot delisted noopept around 2022–2023 following FDA pressure on novel-dietary-ingredient classification. Confirm current availability before relying on this path.
Research-chem (US/intl) Phenethylamines Lab / Kimera Chems / Nootropic Source ~$15–30 / 10 g powder Medium-High — COA published per batch US-based, third-party tested. Powder requires accurate scale (10 mg = 0.01 g — small dose, scale precision matters).
iHerb (Swanson) DELISTED — historical only N/A N/A Swanson-branded noopept was previously available on iHerb but has been delisted from US/iHerb supplement channels following FDA novel-dietary-ingredient enforcement. Not a current path.
Avoid Random eBay/Amazon listings Variable Low Noopept on mainstream platforms is suspect.

Sourcing reality 2026: Russian pharmaceutical-grade noopept (Noopept brand, manufactured under Russian GMP) is the canonical source — available via RUPharma and CosmicNootropic at low cost. US research-chem grade is the alternative; mainstream supplement-channel availability has effectively ended following FDA enforcement actions on novel-dietary-ingredient status (~2022–2024). For Dylan: RUPharma alongside his Semax/Adamax order is the cleanest path if added — single-vendor consolidation, Russian pharmaceutical grade, ~$15–25 for a 60-day supply at 20 mg/day.

▸ Biomarkers to track (deep)
  • Baseline (before starting): Subjective cognitive output (verbal fluency, recall, working memory). Headache frequency. Sleep onset latency. Anxiety scale (GAD-7). For Dylan: include baseline 23andMe BDNF Val66Met + APOE status (June 2026 window), bloodwork CBC + LFTs.
  • During use: Subjective verbal fluency / cognitive output rating (daily 1–10 on dosing days). Headache occurrence (proxy for choline cofactor adequacy). Sleep onset latency on dosing days vs non-dosing days. Mood and anxiety changes weekly. For continuous use beyond 4 weeks: rerun CBC + LFTs at 8 weeks. Optional but informative: serum BDNF (LabCorp, ~$80–150) before + after 4 weeks of dosing — if Dylan tries noopept, this is a chance to actually measure the BDNF claim in his own system.
  • Post-cycle (if cycled): Same subjective ratings 1, 2 weeks after stopping. Watch for residual benefit decay curve — Russian clinical data suggests benefit persists 2–4 weeks post-discontinuation, consistent with BDNF transcriptional mechanism.
▸ Controversies / open debates Live debate

1. The "1000× more potent than piracetam" claim — mass basis, not effect. This is the most-cited and most-misunderstood noopept claim. The figure is correct in the narrow sense that 10 mg noopept produces effects comparable to ~1.6–4.8 g piracetam (per-mass potency ratio ~160–1000× depending on endpoint). It is not correct in the sense that the magnitude of cognitive effect is 1000× stronger — the per-effect difference is more like 2–5× by user reports and Russian comparative studies. The claim is regularly used to imply noopept is dramatically more powerful than other nootropics; this is a misreading. Honest framing: similar order of magnitude effect at 1/100th to 1/1000th the dose. Useful for convenience, not a magic-bullet potency claim.

2. Russian-only evidence base. This is the central honest concern, structurally identical to bromantane/semax/adamax. The strongest body of human noopept data is Ostrovskaya / Zakusov Institute lineage, ~20+ years of Russian clinical practice, registered for Rx use in Russia/Ukraine, but zero independent Western RCTs. A skeptical Western reviewer would correctly note that the entire human efficacy claim rests on a single institutional ecosystem with manufacturer/regulatory ties. Mechanism is well-characterized at the molecular level (cPG generation, BDNF/NGF upregulation, AMPA modulation) but molecular-level mechanism doesn't substitute for population-level efficacy data.

3. BDNF claim in healthy human adults — animal-only data. Ostrovskaya's BDNF/NGF upregulation findings are robust in rat and mouse models. In humans, this has NOT been measured systematically. No published study has shown serum or CSF BDNF elevation in healthy adult humans on noopept. The claim is mechanistically plausible and animal-data-supported, but a literal "noopept raises your BDNF" framing is currently extrapolation, not measurement. (This is a chance for Dylan to actually measure it himself if he tries the compound — pre/post serum BDNF is ~$80–150 at LabCorp.)

4. Endogenous cPG — interesting but underexplored. The mechanistic frame that noopept augments an endogenous human signaling system (cycloprolylglycine) is genuinely interesting and structurally distinguishes noopept from foreign-molecule nootropics. But the role of endogenous cPG itself is not well-characterized — what does it normally signal? Why does pushing it harder produce cognitive benefit? Why would it be safe to push? The Russian literature treats cPG as "a memory-related dipeptide" without much deeper mechanistic justification. This is fascinating territory but underdeveloped.

5. Cognitive enhancement in healthy adults — modest evidence. Same concern as for racetams broadly. The strongest noopept studies are in impaired populations (vascular dementia, post-stroke, MCI). In healthy adults, evidence is largely small Russian volunteer trials + anecdote. Magnitude in already-optimized healthy 20yo is likely smaller than user reports often imply.

6. Mechanism vs racetam classification debate. Noopept is sometimes classified as a racetam due to structural similarity (proline-glycine backbone, registered in the same regulatory class in Russia) and sometimes specifically distinguished from classical racetams (different mechanism: dipeptide prodrug → endogenous metabolite, vs racetam scaffold direct CNS action). Honest framing: noopept is a dipeptide nootropic that overlaps mechanistically with racetams (AMPA modulation, cholinergic effects) but is pharmacologically distinct (BDNF upregulation, cPG generation). Calling it a "racetam" is a useful shorthand but not strictly accurate.

7. The endogenous-metabolite framing — safety implication. Because cPG is endogenous in human CNS, the safety case for noopept is theoretically stronger than for foreign nootropics — augmenting an existing system rather than introducing a foreign one. This argument is plausible but not airtight — many endogenous molecules are dangerous when pushed pharmacologically (insulin, cortisol, glutamate). The fact that cPG is endogenous doesn't automatically make noopept safe; it's one piece of the safety argument, not the whole.

8. iHerb/Swanson historical availability — now ended. Earlier biohacker resources cite Swanson-brand noopept on iHerb and US supplement channels. This is no longer current. FDA enforcement on noopept's novel-dietary-ingredient status (~2022–2024) effectively ended mainstream US supplement-channel availability. Current sourcing is Russian gray-market or US research-chem only. Anyone citing iHerb noopept availability is using outdated information.

▸ Verdict change log
  • 2026-05-06 — Initial verdict: WATCH-LIST, MEDIUM confidence. For Dylan-archetype: credible Russian dipeptide nootropic with interesting mechanism (endogenous cPG augmentation, BDNF/NGF upregulation, AMPA potentiation), reasonable Russian clinical signal in cognitive impairment populations, clean side-effect profile, oral-convenient delivery. But Dylan's V5 stack already covers the same neurotrophic + cognitive + anxiolytic territory through Semax + Bromantane + Adamax + Selank — adding noopept is mechanism-redundant and the marginal contribution is unclear. Verdict would upgrade to OPTIONAL-ADD if (i) Adamax/Semax fail to deliver expected benefit and a different-mechanism Russian compound is wanted, (ii) Dylan wants a sublingual fast-onset oral PRN tool the peptides can't fill, or (iii) bloodwork/genetics findings (Met/Met BDNF, APOE4) suggest stronger response. Verdict would upgrade to STRONG-CANDIDATE only with independent Western RCT replication. Plan: keep on radar; do NOT add as default V5 component; revisit after Dylan's first 4–8 weeks on Adamax+Semax to assess whether a different-mechanism trophic compound is worth adding.
▸ Open questions / gaps Open
  1. Does any independent Western RCT exist or is one in progress? As of 2026, no. This is the single most important gap.
  2. Does noopept measurably raise serum or CSF BDNF in healthy adult humans? Animal data is robust; human data is essentially absent. A pre/post serum BDNF measurement in a Dylan trial would meaningfully fill this gap.
  3. What is the actual effect-magnitude ratio noopept vs piracetam in healthy adults? Mass-basis ~1000×; effect-magnitude unclear, probably 2–5× by user reports — but no rigorous comparative trial.
  4. What is the role of endogenous cPG in human CNS, baseline? Underexplored — Russian literature treats it as "a memory-related dipeptide" without deep mechanistic characterization.
  5. PREP polymorphism effects on noopept response? Untested. Plausible mechanistic candidate.
  6. BDNF Val66Met effects on noopept response? Untested. Mechanistically plausible.
  7. Long-term (>3 months continuous) safety profile? Limited published data. Russian clinical practice cycles at 1.5–3 month intervals.
  8. Does noopept contribute meaningfully on top of a Semax + Adamax stack, or is it mechanism-redundant? Unstudied. This is the Dylan-specific open question — could be answered with a 4-week A/B trial (Semax+Adamax baseline → add noopept → compare subjective + measurable output).
  9. Effect on MMA-relevant skill acquisition (motor learning, technique recall)? Untested. Mechanistically plausible (BDNF + AMPA + cholinergic) but no athletic-population data.
  10. Does the "1000× piracetam" framing damage noopept's reputation by overselling? Probably. Honest framing should emphasize endogenous-metabolite mechanism and convenient dosing rather than potency multiplier.
▸ Sources (full, with our context)
Back to compact view